Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
YUTREPIA
product4 mentionslast seen Nov 10, 2026
Inhaled dry-powder formulation of treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Relationships 14
- YUTREPIAapplies topulmonary arterial hypertension treatment99% confidence3 sources
- Liquidia CorporationdevelopsYUTREPIA99% confidence3 sources
- YUTREPIAdepends onPRINT technology99% confidence2 sources
- YUTREPIAapplies topulmonary hypertension associated with interstitial lung disease treatment99% confidence2 sources
- U.S. Food and Drug AdministrationapprovesYUTREPIA97% confidence1 source
- U.S. Food and Drug AdministrationapprovesYUTREPIA97% confidence1 source
- Liquidia CorporationcommercializesYUTREPIA96% confidence1 source
- Liquidia Technologies, Inc.commercializesYUTREPIA95% confidence1 source
- YUTREPIAcomposed oftreprostinil95% confidence1 source
- U.S. Food and Drug AdministrationapprovesYUTREPIA95% confidence1 source
- YUTREPIAcomposed ofPRINT technology93% confidence1 source
- YUTREPIAapplies topulmonary hypertension treatment90% confidence1 source
- YUTREPIAapplies topulmonary hypertension associated with chronic obstructive pulmonary disease treatment82% confidence1 source
- YUTREPIAapplies tosystemic sclerosis-associated Raynaud's phenomenon treatment82% confidence1 source
Relationship
YUTREPIAapplies topulmonary hypertension associated with interstitial lung disease treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 14, 2026UNITED THERAPEUTICS Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Yutrepia ® product infringes UT's U.S. Patent No. 11,826,327 (the '327 patent ), which expires February 3, 2042, and covers improving exercise capacity in patients suffering from pulmonary hypertension associated with interstitial lung disease ( PH-ILD )
- filingSEC EDGARSep 30, 2026Liquidia Corp 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
approved in 2025 for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)